{"filing":{"accession_number":"0001829126-26-008654","cik":"0001979414","ticker":"NTHI","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"neonctechnologies_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626008654/neonctechnologies_8k.htm"},"events":[{"id":27072,"run_id":24643,"accession_number":"0001829126-26-008654","anchor_item_number":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"The filing discloses positive Phase 2a clinical trial results for NEO100 in recurrent IDH1-mutant high-grade glioma, announced via press release on August 12, 2026. The study met its primary endpoint (six-month progression-free survival of 48.9% vs. 20% benchmark, p=0.0047) with favorable secondary outcomes including median overall survival of 26.09 months and no major toxicities. While this is a clinical-stage biotech company rather than a traditional earnings release, the disclosure of material clinical trial results through a press release furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure) is functionally equivalent to an earnings release—it is a material announcement of significant company results that would affect investor assessment of the registrant's prospects.","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":28441,"accession_number":"0001829126-26-008654","item_number":null,"item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"The filing discloses positive Phase 2a clinical trial results for NEO100 in recurrent IDH1-mutant high-grade glioma, announced via press release on August 12, 2026. The study met its primary endpoint (six-month progression-free survival of 48.9% vs. 20% benchmark, p=0.0047) with favorable secondary outcomes including median overall survival of 26.09 months and no major toxicities. While this is a clinical-stage biotech company rather than a traditional earnings release, the disclosure of material clinical trial results through a press release furnished as Exhibit 99.1 under Item 7.01 (Regulation FD Disclosure) is functionally equivalent to an earnings release—it is a material announcement of significant company results that would affect investor assessment of the registrant's prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T12:32:40.024590+00:00","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-08-12"}]}